Tellus Therapeutics
Chi Hornik, PharmD, Scientific Advisory Board Member, is the Director of Clinical Research in the Division of Pediatric Critical Care Medicine at Duke University. She is a pharmacotherapy specialist, a practitioner in neonatal and pediatric critical care, and has faculty appointments in the Duke School of Medicine and the Duke Clinical Research Institute (DCRI). In addition to her clinical service in the NICU, Chi’s neonatal clinical research responsibilities include leading multicenter clinical trials through DCRI and serving as site PI on 7 concurrent federal and industry-funded clinical trials at Duke. She also serves as Chair of the Medication Safety Alliance, Team Lead of Maestro Care Builds and coauthor of >70 clinical guidelines in the NICU. Chi received her Doctorate degree from the University of North Carolina at Chapel Hill where she maintains a faculty appointment in clinical education. As a clinician, researcher, and mentor, she is committed to improving the health of all children.
This person is not in the org chart
This person is not in any offices
Tellus Therapeutics
Tellus Therapeutics is developing novel small molecules derived from human maternal breast milk for the treatment of newborns with perinatal brain injury.